LivaNova vs Tandem Diabetes Care
LivaNova reported revenue of $1.4 billion in fiscal 2025, 1.4 times Tandem Diabetes Care's $1.0 billion in fiscal 2025. LivaNova's revenue grew 10.7% in its latest year, and Tandem Diabetes Care's grew 7.9%. LivaNova had an operating margin of 14.4%, against -18.4% at Tandem Diabetes Care. Free cash flow was $173 million at LivaNova and −$30 million at Tandem Diabetes Care.
Side by side
| LivaNova | Tandem Diabetes Care | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.4B | $1.0B |
| Revenue growth | 10.7% | 7.9% |
| Revenue growth a year, last 5 years | 8.2% | 15.3% |
| Gross margin | 67.7% | 53.8% |
| Operating margin | 14.4% | −18.4% |
| Net margin | −17.5% | −20.2% |
| Free cash flow | $173M | −$30M |
| Free cash flow margin | 12.5% | −2.9% |
| Return on capital | 12.8% | −85.5% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −0.1% | 2.8% |
| Last close | $89.99 | $16.91 |
| P/E at the last close | 30.0× | — |
| Insider trades, last 12 months | sold $1.0 million | sold $36,911 |
| Piotroski F-score | 5 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
LivaNovaTandem Diabetes Care
Operating margin
Percent of revenue
LivaNovaTandem Diabetes Care
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
LivaNovaTandem Diabetes Care
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the LivaNova and Tandem Diabetes Care pages.